Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) Director Robert A. Breyer sold 5,000 shares of Alkermes Plc stock on the open market in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $45.12, for a total transaction of $225,600.00. Following the completion of the transaction, the director now directly owns 53,156 shares of the company’s stock, valued at approximately $2,398,399. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

A number of research firms have recently commented on ALKS. Analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Wednesday, August 6th. They now have a $45.00 price target on the stock. Separately, analysts at Credit Suisse cut their price target on shares of Alkermes Plc from $57.00 to $56.00 in a research note on Friday, August 1st. Finally, analysts at Mizuho cut their price target on shares of Alkermes Plc from $61.00 to $59.00 in a research note on Thursday, July 31st. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $48.50.

Alkermes Plc (NASDAQ:ALKS) traded down 1.48% on Tuesday, hitting $44.07. 779,476 shares of the company’s stock traded hands. Alkermes Plc has a one year low of $29.36 and a one year high of $54.25. The stock’s 50-day moving average is $44.29 and its 200-day moving average is $46.32. The company’s market cap is $6.427 billion.

Alkermes Plc (NASDAQ:ALKS) last announced its earnings results on Thursday, July 31st. The company reported $0.11 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.14 by $0.03. The company had revenue of $153.40 million for the quarter, compared to the consensus estimate of $146.91 million. During the same quarter last year, the company posted $0.30 earnings per share. Alkermes Plc’s revenue was up 10.7% compared to the same quarter last year. Analysts expect that Alkermes Plc will post $0.27 EPS for the current fiscal year.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.